Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Net Income

Bottom-line profit after all expenses, interest, and taxes.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Net Income · Q3 FY2026 · quarter ended Mar 2026

Net income of -$14.98M in Q3 FY2026

Q3 FY2026 net income was -$14.98M. Trailing-twelve-month net income was -$34.09M.

Context

  • Net income amounted to 30.0% of revenue in FY2025, up 20.7 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$16.71M (+56.8%) for the fiscal year ending May 2026, a step up from the -422.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.98M-88.0% QoQ
Last fiscal yearMay 2025
-$38.72M-422.3% YoY
LTMMar 2026
-$34.09M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-422.3%+56.8%+479.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(38.72M) USD
Year-over-year change
-422.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Net income amounts to 25.2% of revenue for LFCR, versus a peer median of 103.3%.
LFCR Competitors
Net Income for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.17M USD+26.3%—41.1%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$34.09M USD——25.2%
SGHTSight Sciences, Inc.LTM Mar 2026-$37.25M USD+24.6%—46.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.62M EUR-51.2%—339.4%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$51.99M USD-12.6%——
CVRXCVRx, Inc.LTM Mar 2026-$52.66M USD-2.2%—89.1%
IMMPImmutep LimitedFY2025-A$61.43M AUD-43.8%—1218.0%
ACBAurora Cannabis Inc.LTM Mar 2026-CA$75.03M CAD-4815.8%—24.1%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
CGCCanopy Growth CorporationLTM Mar 2026-CA$366.64M CAD+38.7%—117.4%
Peer median (excluding LFCR) —-12.6%—103.3%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.